FDA declines full approval for Intercept's liver disease drug

The U.S. Food and Drug Administration on Tuesday declined full approval for Intercept Pharmaceuticals’ liver disease drug, raising questions about its future in the market.

The drug, Ocaliva, will continue to be available in the U.S. under the accelerated approval status, the company said.